Abstract:There is no consensus for the treatment of recurrent rectal cancer. As FOLFOX has been the standard adjuvant chemotherapy, most recurrent patients have received oxaliplatin previously. This study is to investigate the local effect and toxicity of irinotecan and capecitabine concurrent with intensity-modulated radiation therapy in the treatment of recurrent rectal cancer. Fifty-eight patients (median age 53 years; m/f: 37:21) diagnosed with recurrent rectal cancer were treated in our hospital from October 2009 to November 2011. Eighty-two recurrent sites in all patients were included in which there were 27 cases with single site and 31 cases with multiple ones. Thirty-nine patients were confirmed recurrent rectal cancer without extra pelvic metastases while 19 patients with extra pelvic metastases. All patients underwent pelvic intensity-modulated radiation therapy of 45 Gy (1.8 Gy per fraction) followed by a boost of 10 Gy to 16 Gy (2 Gy per fraction) to the recurrent tumors. The concurrent chemotherapy regimen was irinotecan 50 mg/m2, weekly and capecitabine 625 mg/m2, bid (Mon-Fri.). Radical surgery was recommended if patients without extra pelvic metastases and the recurrent lesions were evaluated as resectable. The patients were follow-up every 3 months with clinical examinations, abdominal and pelvic CTs or MRIs. Tumor response was evaluated using CT/MRIs according to the RECIST criteria or postoperative pathological findings. NCI-CTC 3.0 was used to score the toxicities. The entire cohort included 82 recurrent sites, for the location of them, 30 sites were in peri-rectal region, 22 in pre-sacral region, 4 at external iliac nodal region, and 3 at inguinal nodal region. Eleven patients with locally recurrent rectal cancer underwent radical resections (R0) post chemoradiation. The pathologic complete response was observed in 7 of 11 patients. Clinical complete response was observed in 1 patient (1.7%) and partial response was 19 patients (32.8%). Only 4 patients showed progressive disease during or shortly after treatment. Of 41 symptomatic patients, clinical complete and partial symptom reliefs with chemoradiation were achieved in 56.1% and 36.6%. Only 2 patients experienced grade 4 leukopenia. The more common grade 3 toxicities were diarrhea (14 patients). In addition, grade 3 radiation dermatitis, leukopenia, and cystitis were observed in 5, 4, and 2 patients, respectively. This study showed irinotecan and capecitabine concurrent with intensity-modulated radiation therapy can relieved local symptoms significantly and exhibited promising efficacy with manageable toxicities in the recurrent rectal cancer. To improve the R0 resectable rate will be investigated in further study.

Pathological Complete Response Following Neoadjuvant Radiotherapy and Intraperitoneal Perfusion Chemotherapy for Recurrent Colon Carcinoma: A Case Report and Literature Review

Comparison of Two Different Neoadjuvant Chemoradiatiotherapy Regimens for Locally Advanced Rectal Cancer: Results of a Phase II, Multicenter, Randomized Trial.

Multidisciplinary Evaluation of Locally Advanced Leiomyosarcoma in the Lower Rectum: a Case Report and Literature Review

Three-dimensional Conformal Radiotherapy Combined with FOLFOX4 Chemotherapy for Unresectable Recurrent Rectal Cancer

Predictors and Risk Factors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Population-Based Analysis

[A Case of Pathologically Complete Response after Preoperative Chemotherapy in a Locally Advanced Rectal Cancer]

[A Case of Pathological Complete Response of Advanced Rectal Cancer with Direct Invasion of the Prostate and Extra-Regional Lymph Node Metastasis after Chemotherapy]

Changing Patterns of Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Narrative Review

Pathological Complete Response After Neoadjuvant Therapy in Rectal Adenocarcinoma: a 5-Year Follow-up

Survival analysis in patients with pathological complete response of locally advanced rectal cancer after neoadjuvant chemoradiotherapy

Rectal Cancer Survival for Residual Carcinoma In Situ Vs. Pathologic Complete Response After Neoadjuvant Therapy

[Surgical management of patients with pathologic complete response in the primary tumor after neoadjuvant chemotherapy for rectal cancer]

Analysis of response and prognostic factors in the pelvic recurrent rectal cancer after radical surgery

Curative resection after percutaneous drainage followed by preoperative panitumumab monotherapy for locally advanced sigmoid colon cancer with intra-abdominal abscess: a case report

Phase Ii Study of Irinotecan and Capecitabine Concurrent with Intensity Modulated Radiation Therapy in the Treatment of Recurrent Rectal Cancer

Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Cancer

[Pathological Complete Response to Neoadjuvant Chemotherapy for Abscess-Forming Rectal Cancer-A Case Report]

Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review

Pathological Complete Response in Pancreatic Cancer After Preoperative Chemotherapy

Image Guided Concomitant Dose Escalation Neoadjuvant Radiotherapy in Patients with Locally Advanced Mid-low Rectal Cancer

[Predictive factors for pathological complete response to neoadjuvant therapy in locally advanced rectal cancer: a review of current research]